Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rovina, Nikoletta
PRECISION, NCT05926505 / 2023-000102-25: Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome	Recruiting	2/3	182	Europe	Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret]	Hellenic Institute for the Study of Sepsis, Hellenic Institute for the Study of Sepsis	Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID	08/25	08/25
ImmunoSep, NCT04990232 / 2020-005768-74: Personalized Immunotherapy in Sepsis	Active, not recruiting	2	280	Europe	Anakinra or rhIFNγ, Imukin, Kineret, Placebo	Hellenic Institute for the Study of Sepsis	Sepsis	01/25	04/25
NCT06694701: Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)	Not yet recruiting	2	75	Europe	Emapalumab-Izsg, Emapalumab Group 1, Emapalumab Group 2, Placebo	Hellenic Institute for the Study of Sepsis	Sepsis	11/26	11/26